Brown, Québec; R. Faraawi, Kitchener, Ontario; W. Olszynski, Saskatoon, Saskatchewan; L.-G. Ste.-Marie, Québec. Estonia—K. Maasalu, Tartu; K.-L. Vahula, Pärnu; I. Valter, Tallinn. France—C. L. Benhamou, Orleans; R. Chapurlat, Lyon; P. Fardellone, Amiens; G. Werhya, Vandoeuvre-lès-Nancy. Hungary—Á. Balogh, Debrecen; K. Horváth, Győr; P. Lakatos, Budapest; L. Korányi, Balatonfüred; K. Nagy, Eger. Poland—J. Badurski, Bialystok; J. K. Łącki, Warszawa; E. Marcinowska-Suchowierska, Warszawa; A. Racewicz, Białystok. United
States—M. Bolognese, Bethesda, MD; D. Brandon, San Diego, CA; R. Feldman, South Miami, FL; W. Koltun, San Diego, CA; R. Kroll, Seattle, WA; M. McClung, Portland, OR; P. Miller, Lakewood, CO; J. Mirkil, Las Vegas, NV; A. Moffett, Jr., Leesburg, FL; S. Nattrass, Seattle, WA; #learn more randurls[1|1|,|CHEM1|]# C. Recknor, Gainesville, GA; K. Saag, Birmingham, AL; J. Salazar, Melbourne, FL; R.A. Samaan, Brockton, MA; Talazoparib solubility dmso S. Trupin, Champaign, IL; M. Warren, Greenville, NC; R. Weinstein, Walnut Creek, CA. Conflicts of interest Dr. McClung has received grants and/or is a consultant for Amgen, Lilly, Merck, Novartis, and Warner Chilcott. Dr. Miller is consultant and/or a member of the Speakers
or Advisory Boards of Amgen, Eli Lilly, Genentech, GlaxoSmithKline, Merck, Novartis, and Warner Chilcott. Dr. Brown is a consultant to Abbott, Amgen, Eli Lilly, Merck, Novartis, and Warner Chilcott, a board member of Amgen, Eli Lilly, Novartis, and Warner Chilcott, and a member of the Speakers’ Bureaus for Amgen, Eli Lilly, Merck, Novartis, and Warner Chilcott. Dr. Zanchetta has received grants from Amgen, Eli Lilly, Merck, Pfizer, Procter & Gamble, and Warner Chilcott Pharmaceuticals. He is a consultant and/or member of Advisory Boards for Amgen, Eli Lilly, GlaxoSmithKline, Merck, Pfizer, and Servier. Dr. Bolognese is a lecturer and/or member of the Speakers’ Bureaus
for Amgen, Lilly, and Genentech. O-methylated flavonoid Dr. Benhamou is a board member of Amgen, Novartis, and Merck, a member of the Speakers’ Boards for Amgen, Servier, Novartis, and Roche, and has received grants from Amgen and Servier. Dr. Balske was previously employed by and holds stock in the Procter & Gamble Company. Mr. Burgio is employed by and holds stock in the Procter & Gamble Company. Mr. Sarley was previously employed by Warner Chilcott Pharmaceuticals and the Procter & Gamble Company and holds stock in the Procter & Gamble Company. Ms. McCullough was previously employed by Warner Chilcott Pharmaceuticals and the Procter & Gamble Company and holds stock in the Procter & Gamble Company. Dr. Recker is a consultant for Amgen, GlaxoSmithKline, Lilly, Merck, Novartis, NPS Allelix, Procter & Gamble, Roche, and Wyeth, and has received grants/research support from Amgen, Glaxo Smith Kline, Lilly, Merck, Novartis, NPS Allelix, Procter & Gamble, Roche, sanofi aventis, and Wyeth.